ketorolac has been researched along with mifepristone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Blais, V; Rivest, S; Zhang, J | 1 |
1 review(s) available for ketorolac and mifepristone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for ketorolac and mifepristone
| Article | Year |
|---|---|
In altering the release of glucocorticoids, ketorolac exacerbates the effects of systemic immune stimuli on expression of proinflammatory genes in the brain.
Topics: Adrenal Glands; Animals; Brain; Chemokine CCL2; Corticosterone; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Feedback; Gene Expression; Glucocorticoids; Hypothalamus; I-kappa B Proteins; Immunity; Inflammation; Interleukin-1; Isoenzymes; Ketorolac; Male; Microcirculation; Mifepristone; NF-KappaB Inhibitor alpha; Pituitary Gland; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; RNA, Messenger; Signal Transduction; Tumor Necrosis Factor-alpha | 2002 |